Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5%

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price dropped 5% on Monday . The company traded as low as $38.50 and last traded at $38.79. Approximately 110,941 shares changed hands during trading, a decline of 86% from the average daily volume of 787,334 shares. The stock had previously closed at $40.84.

Analysts Set New Price Targets

GPCR has been the topic of a number of analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Structure Therapeutics in a report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday. JMP Securities decreased their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, BMO Capital Markets increased their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, June 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $84.63.

Structure Therapeutics Trading Down 0.5 %

The stock’s fifty day moving average price is $38.09 and its 200 day moving average price is $39.64. The stock has a market cap of $1.78 billion, a P/E ratio of -49.69 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, analysts anticipate that Structure Therapeutics Inc. will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GPCR. Franklin Resources Inc. grew its holdings in shares of Structure Therapeutics by 116.2% during the 4th quarter. Franklin Resources Inc. now owns 542,323 shares of the company’s stock valued at $22,105,000 after purchasing an additional 291,503 shares during the last quarter. TD Asset Management Inc grew its holdings in Structure Therapeutics by 3.3% in the 4th quarter. TD Asset Management Inc now owns 157,258 shares of the company’s stock worth $6,410,000 after acquiring an additional 5,082 shares during the last quarter. Capital International Investors bought a new stake in Structure Therapeutics in the 4th quarter worth $34,647,000. Capital Research Global Investors grew its holdings in Structure Therapeutics by 182.3% in the 4th quarter. Capital Research Global Investors now owns 973,535 shares of the company’s stock worth $39,681,000 after acquiring an additional 628,687 shares during the last quarter. Finally, Capital World Investors grew its holdings in Structure Therapeutics by 531.6% in the 4th quarter. Capital World Investors now owns 634,160 shares of the company’s stock worth $25,848,000 after acquiring an additional 533,760 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.